DBV Technologies
USUSDDBV Technologies (US:DBVTF) — Biotechnology: Biological Products (No Diagnostic Substances). Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 3. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie įmonę
- Svetainė
- dbv-technologies.com
- Investuotojams
- dbv-technologies.com/investor-overview/
- Sektorius
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Būstinė
- CHATILLON, France
- Generalinis direktorius
- Mr. Daniel Tassé
- Darbuotojai
- 170
- Įkurta
- 2002
- Apyvartoje esančios akcijos
- 296.06 mln. 2026-07-16 duomenimis
- Laisvai apyvartinės akcijos
- 34.94 mln.
- Rinkos kapitalizacija
- 731.56 mln. USD
- Insaideriai
- 0%
- Instituciniai investuotojai
- 41.66%
- Šaka (SIC)
- Biological Products, (No Diagnostic Substances)
- Teisinė forma
- K65D
- ISIN
- FR0010417345
- LEI
- 969500PVBQFWQKVDMD80
Aprašymas
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Dividendai
Dividendų išmokų nerasta (patikrinta 07.10.2026). Įmonė greičiausiai nemoka dividendų.
Šios savaitės naujienos
Naujienų iš įmonės svetainės kol kas nėra.
Didžiausi akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos data |
|---|---|---|---|
| MPM Bioimpact LLC | 5.83% | 3.67 mln. | 2026-06-30 |
| Siren, L.L.C. | 2.95% | 1.86 mln. | 2026-06-30 |
| Vivo Capital, LLC | 2.93% | 1.84 mln. | 2026-06-30 |
| Perceptive Advisors Llc | 2.63% | 1.65 mln. | 2026-06-30 |
| Baker Bros. Advisors, LP | 2.32% | 1.46 mln. | 2026-06-30 |
| Artisan Partners Limited… | 2.18% | 1.37 mln. | 2026-06-30 |
| UBS Group AG | 2.09% | 1.31 mln. | 2026-06-30 |
| Morgan Stanley | 1.52% | 954 908 | 2026-06-30 |
| Logos Global Management… | 1.46% | 915 000 | 2026-06-30 |
| Patient Square Capital L… | 1.45% | 909 474 | 2026-06-30 |
| Artisan Partners Funds I… | 1.34% | 840 251 | 2026-06-30 |
| Fidelity Advisor Series… | 0.68% | 428 800 | 2026-07-31 |
| iShares Trust-iShares Co… | 0.3% | 942 528 | 2026-08-31 |
| MOHIDEEN PHARIS (Officer… | ≈0.23% | 144 995 | 2026-01-29 |
| iShares Trust-iShares MS… | 0.21% | 666 480 | 2026-08-31 |
| Ikarian Capital, LLC | 0.19% | 525 000 | 2025-12-31 |
| RUSSELL INVESTMENT CO-Ta… | 0.07% | 45 089 | 2026-04-30 |
| College Retirement Equit… | 0.04% | 117 668 | 2026-06-30 |
| RUSSELL INVESTMENT CO-U.… | 0.04% | 22 707 | 2026-04-30 |
| Fidelity Salem Street Tr… | 0.03% | 108 080 | 2026-07-31 |
| SPDR INDEX SHARES Fd.S-S… | 0.03% | 105 233 | 2026-07-31 |
| Fidelity Concord Street… | 0.02% | 51 082 | 2026-07-31 |
| Fidelity Concord Street… | 0.02% | 12 855 | 2026-07-31 |
| iShares Trust-iShares Co… | 0.01% | 41 182 | 2026-08-31 |
| SPDR-EUROPE-SSgA SPDR ET… | 0.01% | 36 650 | 2026-07-31 |
| SPDR-EUROPE-SSgA SPDR ET… | 0.01% | 28 854 | 2026-07-31 |
| iShares Trust-iShares MS… | 0.01% | 19 527 | 2026-08-31 |
| RUSSELL INVESTMENT FUNDS… | 0.01% | 5 834 | 2026-06-30 |
| Steward Funds Inc-Stewar… | 0.01% | 4 051 | 2026-04-30 |
| LORD ABBETT SECURITIES T… | 0% | 2 973 | 2026-04-30 |
| Trust for Professional M… | 0% | 2 245 | 2026-05-31 |
| Gabelli Healthcare & Wel… | 0% | 400 | 2026-06-30 |
